Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vepugratinib - Loxo Oncology

Next Previous
Drug Profile

Vepugratinib - Loxo Oncology

Alternative Names: LOX-24350; LOXO-435; LY-3866288

Latest Information Update: 02 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Loxo Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Type 3 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Urogenital cancer
  • Phase I Solid tumours

Most Recent Events

  • 12 Dec 2025 Phase-III clinical trials in Urogenital cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable, First-line therapy, Combination therapy) in USA, China (PO) (NCT07218380)
  • 22 Oct 2025 Pharmacodynamics data from a preclinical studies in Urogenital cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025 (AACR-NCI-EORTC-2025)
  • 20 Oct 2025 Eli Lilly and Company plans phase III trial in Urogenital cancer in US, Australia, Brazil, Canada, China, Czechia Republic, Denmark, France, Germany, Hungary, Italy, Japan, Netherlands, Poland, South Korea, Spain, Taiwan, Turkey and United Kingdom in November 2025 (PO) (NCT07218380)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top